Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

lue of third party asset-backed commercial paper amounted to a loss of $1,184,000 for the quarter and year ended December 31, 2007 and represents a provision recorded on the valuation of asset-backed commercial paper held by the Company. Refer to Liquidity and Capital Resources section for more details.

Foreign exchange loss amounted to $54,000 for the current quarter (gain of $1,130,000 for the year), compared to a gain of $245,000 for the same quarter in the previous year (loss of $280,000 for the year). Foreign exchange gains or losses arise on the movement in foreign exchange rates in relation to the Company's net monetary assets denominated in currencies other than US dollars, which is its functional and reporting currency, and consists primarily of monetary assets and liabilities denominated in Canadian dollars. Foreign exchange gains recognized for the year ended December 31, 2007, are mainly attributable to the strengthening of the Canadian dollar compared to the US dollar during the period.

Other income amounted to $287,000 for the current quarter ($1,274,000 for the year), compared to $282,000 for the same quarter in the previous year ($1,348,000 for the year). Other income consists of non-operating revenue, primarily sub-lease revenue. The 2006 income includes an amount of $293,000 in respect of the recovery of prior years' property taxes.

Share of loss in a company subject to significant influence amounted to nil for the current quarter ($327,000 for the year), compared to $489,000 for the corresponding quarter in the previous year ($2,440,000 for the year). Non-controlling interest amounted to nil for the current quarter ($109,000 for the year), compared to $162,000 for the corresponding quarter in the previous year ($801,000 for the year). These items result from the consolidation of the Company's interest in a holding company (Innodia Holding) that owns shares of Innodia Inc., for which Neurochem is the primary beneficiary. The sh
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, Fancyflyingfox.com, ... special occasion clothes, has announced its latest designs of ... addition, all the new elegant outfits are offered with ... place an order before October 30 can enjoy this ... and great marketing strategies, it has become one of ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... OLIVE, N.J., Jan 12 InSet Technologies, an emerging ... targeted delivery of medication, announced today the closing of ... venture capital firm, led the round and was joined ... In conjunction with the financing, Kurt C. Wheeler of ...
... Dr. Schoenhaus Perform Foot Fat Pad Restoration on The Balancing ... with comfort and look great doing it" is more than ... experienced foot surgeon, she is a leading expert and innovator ... and legs, but as a woman, she understands the emotional ...
... business in Louisville, Business First of Louisville has named DRE a 2008 ... ... Inc., a premier international medical and surgical equipment supplier, has ... the Year. The award caps the most successful three-year period in DRE’s ...
... research tools to address large, unwarranted variations in project management, ... , ... Phoenixville, Pennsylvania (PRWEB) January ... large and unwarranted variations in corporate spending. As an example, ...
... a drug development company focusing on serious Central Nervous ... it held an initial closing of $2.9 million in ... use the funds for the clinical development of MCD-386, ... down disease progression and improving memory and cognition in ...
... Tenn., Jan. 11 HotHead Technologies, Inc., ... through,research-based technology, today announced it is working ... viable heat-sensing helmet insert, which can,detect potential ... News of their joint,development activities was officially ...
Cached Medicine News:Health News:InSet Technologies Completes $25 Million Financing 2Health News:Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus 2Health News:Business First Selects DRE Medical Equipment as a Company of the Year 2Health News:Business First Selects DRE Medical Equipment as a Company of the Year 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:New Venture Funding for Alzheimer's Disease Drug Developer 2Health News:HotHead Technologies Working with Schutt Sports to Develop 'Smart' Helmet 2Health News:HotHead Technologies Working with Schutt Sports to Develop 'Smart' Helmet 3
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... key insights is a critical success factor in ... companies must develop market research organizations that effectively ... their location, specialty or service area. ... groups create value and earn recognition from internal ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US ... a leading online community and information resource for neurologists and ... and Alzheimer disease , with discussions of the ... 1 million Americans have Parkinson disease , more than ... or Lou Gehrig disease. Diagnosis can be difficult ...
(Date:10/17/2014)... 17, 2014 According ... by Technique (Optical Coherence Tomography, Hyperspectral Imaging, ... (Ophthalmology, Neurology, Oncology, Cardiology) - Global Forecasts ... the Optical Imaging market over the forecast ... at $917.1 million in 2014 and is ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
... Massachusetts General Hospital (MGH) Cancer Center has purchased four radiation ... Infinity and one Elekta Synergy® S. The order, ... enable the facility to offer patients a complete cancer treatment ... systems position MGH to take advantage of ...
... , MOUNTAIN VIEW, Calif., Oct. 2 Alexza Pharmaceuticals, Inc. ... present a corporate overview during the Fourth Annual JMP Securities ... Hotel in New York. This corporate overview will be ... Eastern Time. , To access the live presentation via the ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference 2Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference 3
... Processing Video Camera is our new generation ... Image Processing (IP) technology, the IP 4.2 ... Exciting new features, enhanced image quality, and ... exceptional value. All IP 4.2 cameras are ...
... full lineup of high-powered Xenon, Metal ... optimal brightness in a durable, lightweight ... highest quality light guide cables, providing ... lightweight, durable design., Powerful illumination and ...
... Due to its design, this ... varieties of stone therapy in urinary ... primarily as a multipurpose lithotripter with ... and percutaneous nephrolithotomy. ,The basic system ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
Medicine Products: